CRISPR, Patents, and Nobel Prizes – lareviewofbooks
lareviewofbooks |
CRISPR, Patents, and Nobel Prizes
lareviewofbooks Nor is this a “how to” book for aspiring do-it-yourself CRISPR users; or a deep analysis of the ethical, legal, and social issues CRISPR and its progeny will raise; or a legal analysis of the already (in)famous CRISPR patent fight; or a look at the … |
Hemophilia News Today |
uniQure Updates Gene Therapy Program in Treatment of Hemophilia B
Hemophilia News Today Recent advances in gene therapy approaches to treat hemophilia B were recently announced by uniQure. The company achieved “substantial progress in advancing our lead program in hemophilia B,” Matthew Kapusta, CEO of uniQure, said in a press … |
Hemophilia News Today |
uniQure Updates Gene Therapy Program in Treatment of Hemophilia B
Hemophilia News Today Recent advances in gene therapy approaches to treat hemophilia B were recently announced by uniQure. The company achieved “substantial progress in advancing our lead program in hemophilia B,” Matthew Kapusta, CEO of uniQure, said in a press … |
UC Berkeley |
Cyborg bacteria turn sunlight into useful chemicals
UC Berkeley “Synthetic biology and the ability to expand the product scope of CO2 reduction will be crucial to poising this technology as a replacement, or one of many replacements, for the petrochemical industry,” he said. Sakamoto and Yang presented their work … ‘Cyborg’ bacteria beat plants at their own gameChemistry World (subscription) Semiconductor nanoparticles give bacteria a boostThe Engineer |
UC Berkeley |
Cyborg bacteria turn sunlight into useful chemicals
UC Berkeley “Synthetic biology and the ability to expand the product scope of CO2 reduction will be crucial to poising this technology as a replacement, or one of many replacements, for the petrochemical industry,” he said. Sakamoto and Yang presented their work … ‘Cyborg’ bacteria beat plants at their own gameChemistry World (subscription) Semiconductor nanoparticles give bacteria a boostThe Engineer |
Myeloma Research News |
Kite Pharma Asks FDA to Pave Way Toward It Holding Clinical Trials of Its Myeloma Therapy KITE-585
Myeloma Research News Because the protein is crucial to myeloma cells’ survival and growth, it is a good target for chimeric antigen receptor T-cell treatments, also known as CAR T-cell therapies. Those therapies use a patient’s own immune cells to combat their disease. The … Kite Pharma, Inc. (NASDAQ:KITE) Traded 21.0% Above Its 50 Day AverageModern Readers Kite Pharma, Inc. (NASDAQ:KITE) Stock Closed Much Higher Than …HugoPress Kite Pharma, Inc. (NASDAQ:KITE) Traded Significantly Above Its 50 …Highlight Press Finance Daily all 21 news articles » |
STAT |
New CAR–T drug for leukemia, while effective, is ‘going to cost a fortune’
STAT The treatment, CTL019, belongs to a new class of medications called CAR–T cell therapies, which involve harvesting patients’ immune cells and genetically altering them to kill cancer. It’s been tested in patients whose leukemia has relapsed in spite of … |